Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
BioConferenceLive

US Pharma CEO Compensation Double That of Europeans

By BiotechDaily International staff writers
Posted on 29 Apr 2013
A new report has found that the CEOs of European pharmaceutical companies continue to receive far less than their US counterparts.

The report, from Bloomberg Industries (New York, NY, USA), found that the median salary for the leading pharmaceutical executives in Europe in 2012 was USD 9.3 million, 46% less than the USD 17.2 million earned by CEOs of U.S.-based pharmaceutical companies. Furthermore, the average pay of USD 13.7 million for large-cap pharmaceutical companies was significantly less than the USD 21.9 million paid to the leaders of industrial companies.

Pfizer (New York, NY, USA) CEO Ian Read topped the list with his 2012 compensation of USD 25.6 million, a 2.5% rise from the previous year. According to Pfizer's proxy statement, 90% of Read's 2012 payout was tied to company performance; he was given USD 1.7 million in salary, USD 6.4 million in stock awards, USD 6.5 million in options, and a USD 3.4 million cash bonus. His total compensation also included a USD 7.1 million change in pension value and nonqualified deferred compensation earnings.

That figure was more than five times greater than the USD 5 million paid to Lars Rebien Sørensen, CEO of Novo Nordisk (Bagsværd, Denmark). Another example involves Novartis (Basel, Switzerland) which had to defend against a backlash when it first proposed paying former Chairman Daniel Vasella a USD 78 million noncompete package when he retired; in February 2013, Novartis backed off the payment to Vasella, and he has since left Switzerland for the US.

“Despite the fact that there’s a lot of noise in Europe on top-management remuneration, we’re actually paying less for management teams, by the look of 2012,” said analyst Sam Fazeli, a London-based analyst for Bloomberg Industries. “US CEOs are paid more; if you want to be competitive, then you’ve got to be competitive.”

Related Links:

Bloomberg Industries
Pfizer
Novo Nordisk



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Microcomputed tomography images (top) and histology images (bottom) of the knees of mice fed a very high fat diet containing omega-3 fatty acid supplement (left) or only omega-6 fatty acids (right) after a knee injury. The omega-6 diet showed abnormal bone remodeling and calcified tissue formation in the joint (white arrow). The omega-6 diet also showed significant loss of cartilage (red staining, yellow arrowhead) and increased joint inflammation (Photo courtesy of Duke University).

Dietary Omega-3 Fatty Acids Moderate Severity of Osteoarthritis in a Mouse Model

Researchers working with an osteoarthritis (OA) obese mouse model found that the fat content of the animals' diet contributed more to the development or arrest of OA than did body weight.... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.